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AB S T A R CT  
This study was aimed at highlighting on the prevalence of malaria among pregnant women in Nigeria 
within the last ten years. The prevalence of congenital malaria in Nigeria varies and it affects every 
geopolitical zone in Nigeria. This is because Nigeria like other countries in the tropics and subtropics 
has factors which favour the survival of mosquito. Although the World Health Organization (WHO) 
recommends the use of insecticide treated nets and effective case management of uncomplicated 
malaria as a feasible and cost-effective control strategy, Nigeria remains one of the worst affected 
countries in the world with malaria among pregnant women and neonates. This paper recommends 
more programs to the menace of this infection among pregnant women and neonates in Nigeria. 
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1 Introduction  
Malaria is a serious public health challenge and a 
major cause of maternal and infant morbidity and 
mortality in malaria–endemic countries [1]. 
Malaria in pregnancy is associated with higher 
rates of parasitemia, severe anemia, 
hypoglycemia, and acute pulmonary edema than 
malaria in non–pregnant women [2]. Also, 
Plasmodium falciparum–infected red cells sequester 
in the placenta, disrupting nutritional exchange 
between mother and fetus and causing 
intrauterine growth retardation, abortion, 
stillbirth, and low birth weight may occur [3]. In 
a World Malaria Report, Nigeria accounts for a 
quarter of all malaria cases in the 45 malaria–
endemic countries in Africa clearly showed the 
challenge of malaria in Nigeria [4].  
The main strategy of malaria control is the 
effective case management of malaria which 
involves proper clinical assessment, laboratory 
confirmation of the disease by using light 
microscopy or rapid diagnostic technique (RDT) 
before treatment with an effective antimalarial 
therapy [5]. Most cases of malaria cases in Nigeria 
are caused by Plasmodium falciparum and it is the 
most virulent of all the species mostly causing 
malaria–related morbidity and mortality in the 
country [6]. This study was aimed at highlighting 
on the prevalence of malaria among pregnant 
women in Nigeria from 2007 to 2017; factors 
contributing to the prevalence of the infection 
and the needed efforts for control.  
2 Epidemiology of Malaria  
Epidemiology of malaria among pregnant 
women in Nigeria Malaria is a zoonetic disease 
transmitted through female mosquito vector of 
Anopheles funestus, Anopheles moucheti, Anopheles 
gambiae and Anopheles arabiensis. It is caused by 
parasitic protozoans of the genus Plasmodium with 
species falciparum, vivax, malariae, ovale and knowlese 
[1,7,8]. Of all the species of human plasmodia, 
Plasmodium falciparum is the most pathogenic as it 
presents malignancy in the type of malaria 
associated with it. In non–immune subject, this 
type of malaria usually run an acute course and 
terminates fatally if not quickly treated with 
specific drugs [8]. According to WHO [9], malaria 
parasite is generally with the tropical and 
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subtropical regions because the development in 
the mosquito is greatly retarded when the 
temperature is below 20oC.  
Malaria in pregnancy is a major contributor of 
maternal and neonatal mortality [10]. According 
to WHO, there were more than 200 million 
malaria cases in 2012.  An estimated 627,000 
people died from malaria in 2012 and 90% of 
them were in Sub–Saharan Africa. Nigeria, the 
Democratic Republic of Congo, Uganda, 
Ethiopia and Tanzania account for 50% of the 
global deaths and 47% of all malaria cases 
(WHO, 2015). The greater percentage of cases 
occurs in children under the age of five years and 
pregnant women [11].  
According to Table 1 presenting malaria 
prevalence among pregnant women in Nigeria 
between 2007 and 2017, there is a variation in 
congenital malaria prevalence and it affects all the 
geopolitical regions in Nigeria. This highlights the 
health importance of malaria as a major public 
health issue in Nigeria.  Apart from being the 
underlying cause of most mother and child death, 
it also causes serious complications in pregnant 
women which result to low birth weight in new 
born neonates, high placental plasmodia burden 
and foetal complications [12,13]. Malaria 
transmission in Nigeria occurs all year round with 
a major peak during the rainy season and the rains 
are longer in the south and shorter in the drier 
northern parts of the country [14].   
Table 1: Malaria prevalence among pregnant women in Nigeria between 2007 and 2017 
Source Year Geographical zone 
 





[15]  2007 South West 72.0% Cross sectional 
[16]  2007 South South 10.0% Cross sectional 
[17]  2007 North East 22.1% Cross sectional 
[18]  2007 South East 15.0% Cross sectional 
[19]  2008 South East 19.7% Cross sectional 
[20]  2009 South West 7.7% Cross sectional 
[21]  2009 South East 58.4% Cross sectional 
[22]  2009 South East 16.0% Cross sectional 
[23]  2010 South South 95.4% Cross sectional 
[24]  2010 South West 52.0% Cross sectional 
[25]  2010 North Central 42.3% Cross sectional 
[26]  2011 North Central 71.6% Cross sectional 
[27]  2011 South East 20.0% Cross sectional 
[28]  2012 South South 78.9% Cross sectional 
[29]  2013 North West 36.0% Cross sectional 
[30]  2013 South South 74.0% Cross sectional 
[31]  2013 South South 26.0% Cross sectional 
[32]  2014 South South 42.0% Cross sectional 
[33]  2015 North Central 88.0% Cross sectional 
[34]  2015 South South 40.6% Cross sectional 
[35]  2015 North West 41.6% Cross sectional 
[36]  2015 South East 99.0% Cross sectional 
[37]  2016 South West 60.6% Cross sectional 
[38]  2016 South West 49.8% Cross sectional 
[39]  2016 South East 73.1% Cross sectional 
[40]  2017 South South 31.3% Cross sectional 
[41]  2017 South East 41.0% Cross sectional 
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Figure 1: Generalized life cycle of malaria parasite [44] 
 
3 Life Cycle of Malaria Parasites  
Although the life cycles of the four species of 
human malaria parasites are not identical, they are 
sufficiently alike to permit a general description 
[43]. The life cycle of Plasmodium parasites can 
be divided into three stages; the exo–erythrocytic 
or pre–erythrocytic stage which usually occurs in 
the liver, the erythrocytic stage which occurs in 
the erythrocytes, and the sexual stage which 
occurs in the mosquito as shown in Figure 1.  
In exoerythrocytic schizogony, an infected 
female anopheline mosquito introduces 
sporozoites into man during feeding. These 
sporozoites are taken up by the blood stream and 
within thirty minutes, they disappear from the 
blood stream. The sporozoites are elongate 
bodies measuring about 11µm in length, with a 
central nucleus. The sporozoites enter the liver 
cells (hepatocytes) and develop into cryptozoites 
giving rise to metacryptozoites. This rapid 
multiplication by schizogony is referred to as 
pre–erythrocytic schizogony [45]. The 
metacryptozoites divide several times over a 
period of six to nine days to produce thousands 
of merozoites which are released into the blood 
circulation and this marks the end of the pre–
erythrocyte stage. In Plasmodium vivax and 
Plasmodium ovale, some injected sporozoites 
may differentiate into dormant forms called 
hypnozoites which may remain in the liver cells 
for sometimes before it undergoes schizogony to 
cause relapse of infection when the red cells are 
invaded [45]. 
In the erythrocytic schizogony, the merozoites 
enter into the bloodstream through the process 
of endocytosis (recognition and attachment of 
the merozoites to the erythrocyte membrane). 
On entry into the red blood cell (erythrocyte), a 
merozoite assumes the appearance of a small 
chromatin mass situated at the periphery of a 
larger mass of cytoplasm, in which a vacuole 
appears. Because of its characteristic appearance, 
this early trophozoite stage is referred to as a 
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“signet ring”. As it grows into maturity, it 
assumes an amoeboid shape as its nucleus divides 
to form up to 20 or more merozoites, depending 
on the Plasmodium species. The dividing stage is 
called a schizont. The mature schizont often 
called a segmenter causes the infected erythrocyte 
to rupture to produce more merozoites which are 
released within 48 to 72 hours due to the 
destruction of the red blood cells for the 
manifestation of human malaria depending on 
the species and which then immediately invade 
additional erythrocytes. This schizogony cycle 
often continues until it is controlled by the 
immune response or chemotherapy or until the 
patient dies in the case of Plasmodium falciparum 
[45, 46].  
The schizont also releases pigments and waste 
products in addition to the merozoites attack are 
responsible for the feverish condition shown by 
high temperature. Merozoites of some 
Plasmodium species selective attack erythrocytes 
of certain age. For instance, merozoites of 
Plasmodium vivax attack young immature red 
blood corpuscles called reticulocytes, those of 
Plasmodium malariae attack the older erythrocytes 
while those of Plasmodium falciparum attack any 
available erythrocyte [47].  
Some merozoites after several generations of 
erythrocytic schizogony differentiate into sexual 
stage called gametocytes. The male cells 
(microgametocytes) and the female cells 
(macrogametocytes) circulate in the blood until 
they either perish or are ingested by a female 
anopheline mosquito. The stage in the mosquito 
begins after a blood meal by a female anopheline 
mosquito, ingesting all the Plasmodium stages 
present in the blood stream but only the 
gametocytes survive to establish the sporogony 
cycle in the mosquito. The male gametocyte is 
called microgametocytes while the female 
gametocyte is called macrogametocyte. In the 
midgut of the mosquito, the macrogametocyte 
develops a small amount of chromatin, and is 
thus transformed into a macrogamete. Equally in 
the mosquito midgut, the microgametocyte 
develops four to eight hair–like flagella 
(exflagellation) and is transformed into 
microgamete. The microgametes detach 
themselves and swim freely about in the fluid 
filled lumen of the midgut until they contact a 
macrogamete where penetration is quickly 
accomplished. The fertilized macrogamete called 
a zygote develops into a mobile ookinete. The 
ookinete within 24 hours penetrates the stomach 
wall of the mosquito between the cells and 
develops as an oocyst and attaches to the motile 
midgut wall to encyst on the basal lamina, the 
extra cellular matrix layer separating the 
haemocoel from the midgut. The oocyst 
gradually matures producing a spherical mass 
within which sporozoites develop mitotically. 
The oocyst usually matures within 10 to 20 days 
depending on the external environmental 
conditions, Plasmodium species and 
physiological characteristics of the anopheline 
mosquito, attending a body size of 50–60µm [48].  
On rupture of the mature sporocyst by the 
oocysts, the sporozoites are released and they 
migrate through the haemocoel (body cavity) to 
the salivary glands to complete the cycle 
approximately 7 to 18 days after ingestion, 
depending on host parasite combination and 
external environmental condition. On feeding, 
the sporozoites are injected into the tissues or 
directly into the blood stream of the new host 
(man) to initiate a new schizogony cycle. All 
stages in the life cycle are thought to be haploid, 
apart from the diploid zygote, which immediately 
after fertilization undergoes a two–step cycle 
meiotic division, the resulting cell containing a 
nucleus with four haploid genomes. The sexual 
process and meiotic division following 
fertilization allow genetic makeup of the 
sporozoites and together with mutations 
provides the raw material upon which selective 
pressures such as antimalarial drugs can work [46, 
48].  
4 Transmission of Malaria  
Malaria is transmitted in various ways by 
mosquito injection of sporozoites; by the transfer 
of erythrocytic stages other than gametocytes; 
and in a blood transfusion. Furthermore, blood 
donation from semi–immune persons without 
clinical symptoms may contain malarial parasites. 
In congenital malaria, infected mothers transmit 
parasites to their children before or during birth 
[49].   
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There are several factors which promote the 
transmission of malaria. These factors include the 
status of the parasite, the vector and the human 
host which interacts with one another and also 
with the biological and physical environment 
[50]. Malaria transmission in an area may be 
stable or unstable [51]. Stable malaria occurs 
when a population is continuously exposed to a 
fairly constant rate of malarial inoculation, while 
unstable malaria occurs seasonally with marked 
changes in transmission from one season to 
another and from one year to the other [52]. 
Carter & Mendis [52] noted that the differences 
in stability of malaria transmission, notably 
between tropical Africa and most other malarious 
regions are largely due to the behaviour and other 
biological characteristics of the regional species 
and subspecies of Anopheles vectors and their 
environments [53,54]. The climatic conditions 
are also the determining factor to the 
transmission of malaria. This supports longevity 
of the vector mosquitoes and rapid development 
of the parasites within them [55]. All of these 
features enable stable and indeed, generally 
intense malaria transmission in the tropics, 
notably Africa [52].  
5 Immunity to Malaria  
Those in malarious areas have developed 
immunity for malaria while immunity is unable to 
reach a high level in unstable malaria area [54]. 
There are two types of clinical immunity in 
malaria. They are immunity which reduces the 
risk of death from malaria and the immunity 
which reduces the intensity of clinical symptoms. 
A third type is antiparasitic immunity which 
directly reduces the numbers of parasites in an 
infected individual [52]. The number of infected 
malaria parasites and the intervals between them 
are all important to determining the malaria 
immune status of an individual. In the case of 
acute attacks of Plasmodium falciparum malaria, it is 
possible that a degree of immunity to some 
aspects of severe life–threatening disease may be 
achieved after only one or two infections [56] and 
clinical immunity to other non life–threatening 
clinical effects of malaria requires more and 
frequent infections by malaria parasites [57]. Due 
to the time taken to achieve effective immunity 
to malaria under conditions of endemic infection, 
antimalarial immunity is often said to be “age 
dependent”. Very young children appear to have 
a poor capacity to acquire effective protective 
antimalarial immunity of any sort, while older 
children and adults may do so more readily [58].  
6 Symptoms of Malaria  
Symptoms of Plasmodium falciparum infection may 
include fever, chills, sweats, cough, diarrhea, 
respiratory distress and headache [59]. The 
symptoms of other species of malaria parasite 
infections may begin with indefinite malaise and 
a slow rising fever several days in duration, 
followed by shaking chills and rapidly rising 
temperature, usually accompanied with headache 
and nausea, and ending with profuse sweating. 
After a period free of fever, the cycle of chills, 
fever and sweating is repeated every one to three 
days [59, 60].    
7 Diagnosis of Malaria  
The gold standard in the diagnosis of malaria is 
microscopy. This involves the demonstration of 
the malaria parasites in blood films, which could 
be either thick or thin [61]. Other supportive 
techniques include sophisticated indirect 
fluorescent antibody (IFA) test, immunoglobulin 
values and haemagglutination tests and molecular 
techniques [48]. In recent years, several malaria 
rapid test kits have been developed for the 
detection of specific malaria antigen–antibody 
[62].    
8 Control Strategies of Malaria in 
Nigeria  
Malaria in pregnancy is a major preventable cause 
of maternal morbidity and poor birth outcomes. 
To prevent the adverse outcomes of malaria in 
pregnancy, WHO [1] recommends the use of 
insecticide treated mosquito nets and effective 
case management of malaria and anaemia in 
pregnant women. In areas of moderate to high 
malaria transmission of sub–Saharan Africa, 
WHO [1] also recommends intermittent 
preventive treatment in pregnancy with 
sulfadoxine pyrimethamine (SP). In recent years, 
an alternative preventive strategy consisting of 
intermittent screening and treatment in 
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pregnancy using rapid diagnostic tests (RDTs) 
during antenatal care visits has been evaluated in 
several countries. Moreover, multiple studies 
have assessed the safety of using artemisinin–
based combination therapies (ACTs) in the first 
trimester of pregnancy WHO [1]. FMOH [63] 
focuses on the following main strategies:   
i. Management of cases  
ii. Prevention of malaria with insecticide–
treated nets (ITN), and   
iii. Use of intermittent preventive treatment 
(IPT) during pregnancy.    
According to Mazumdar & Mazumdar [64], the 
first strategy entails diagnosis to ensure that at 
least 80% of the people at risk of malaria take 
prompt and effective treatment within 24 hours 
of start of illness due to malaria. Under this 
scheme, the children under five will receive free 
Artmether–Lumefantrine (AL) through public 
sector and faith based health facilities.  
A home based case management strategy has 
been planned especially for the children less than 
5 years of age.  The second intervention strategy 
is called the Integrated Vector Management 
system. This process is designed to ensure that at 
least 80% of the population at risk of malaria 
sleeps under insecticide treated nets. Other 
programs meant for children such as 
Immunization Plus Days and Measles campaigns 
had been used as an opportunity to reach a larger 
number of children in the country. Under this 
scheme it is proposed that the Long Lasting 
Insecticide Nets be given to pregnant women 
attending first ante natal care [64].   
The third intervention strategy was formulated 
due to the emergence of multi–drug resistance of 
malaria parasites to Chloroquine (CQ) and 
Sulfadoxine–pyrimethamine (SP) which were 
first–and and second–line treatment respectively 
for uncomplicated malaria in Nigeria, a review of 
the antimalarial treatment policy was enacted 
[65,66]. In line with WHO recommendation for 
treatment of uncomplicated malaria using 
Artemether–lumefantrine and Artesunate–
amodiaquine which showed more efficacy than 
CQ or SP, the Federal Government of Nigeria 
reviewed the treatment policy of uncomplicated 
malaria to the treatment policy for uncomplicated 
malaria to ACT in 2005 [67].  
9 Conclusion  
Malaria infections are highly prevalent in Nigeria 
and a leading cause of maternal neonatal 
morbidity. Plasmodium falciparum which is the most 
pathogenic Plasmodium species accounts for 
most cases of these infections in Nigeria. The 
effectiveness of interventions through effective 
management of uncomplicated malaria and 
sleeping under insecticide treated nets has been 
demonstrated to be cost–effective and feasible. 
There is therefore need to intensify awareness on 
the appropriate management of uncomplicated 
malaria and the advantages of using the long 
lasting insecticide nets to minimize and possibly 
eliminate the adverse effects of malaria in 
pregnant women and newborns.  
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